Molsidomine 4mg tablets
Requires a prescription from a doctor or prescriber
Molsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Molsidomine
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · Randomised trials: 2 · 1980–2026
Showing the 50 most relevant studies, sorted by most relevant.
J. Wöhrle, M. Höher, T. Nusser, et al.
The Canadian journal of cardiology, 2003
Roger Messin
American Heart Journal, 1985
J. Lablanche, G. Grollier, J. Lusson, et al.
Circulation, 1997
T. Chistyk
Hypertension, 2018
B. Rosenkranz, B. Winkelmann, M. Parnham
Clinical Pharmacokinetics, 1996
Majid Pa, P. deFeyter, E. E. V. D. Wall, et al.
The New England journal of medicine, 1980
Hojeong Yoon, Seongchul Park, M. Lim
The journal of physical chemistry letters, 2023
- Nitrosamines
- Molsidomine
Pétry N, Luttringer F, Bantreil X, et al.
2023
- Sydnones
Sydnones are heterocyclic compounds which display important biological activities, including their abilities to react in 1,3-dipolar additions for applications in the development of new prodrugs. Capitalizing on our preliminary work on the mechanosynthesis of sydnones, an extension of this work to two related families of molecules, diarylsydnones and iminosydnones is reported. A ball-milling approach towards the synthesis of diaryl sydnones was developed, a necessary step for the synthesis of potential sydnone-based ligands of metal complexes. A mechanochemistry-based synthesis of iminosydnones was optimized, including the preparation of active pharmaceutical ingredients (API) related to feprosidnine, linsidomine, mesocarb and molsidomine. This work demonstrated that the ball-milling procedures were efficient and time saving through avoiding purification steps, and reduced the use of organic solvents.
Abstract licence: CC BY-NC
I. Utkina-Sosunova, A. Chiorazzi, Mariàngels de Planell-Saguer, et al.
Scientific Reports, 2024
- Vincristine
- Molsidomine
- Neuroprotective Agents
Lamprini Katsanou, Evangelia Fragkiadaki, Sotirios Kampouris, et al.
International Journal of Molecular Sciences, 2023
- Ketamine
- Clozapine
- Cognitive Dysfunction
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Molsidomine, a cardiovascular drug, acts in a similar fashion to organic nitrates.
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1 to 2 hours
Volume of distribution
98 L
Metabolism
95.5%
Clearance
90%
About 2% of the ingested drug is excreted unchanged in the urine.…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[L1370][L1371]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 195 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Oral absorption of Molsidomine is found to be 95.5% ±4.5. Presystemic metabolism is noted to be 56% and metabolism is reported extensive by Liver. Renal Excretion accounts for 95 % and plasma half-life is 5 hr.
Back to top
About 2% of the ingested drug is excreted unchanged in the urine.
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC C01DX12
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Molsidomine
Additional database identifiers
ChemSpider
4090
BindingDB
39912
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4684
GeneCards
GUCY1A2
GenBank Gene Database
X63282
GenBank Protein Database
31671
UniProt Accession
GCYA2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:4684
GeneCards
GUCY1A2
GenBank Gene Database
X63282
GenBank Protein Database
31671
UniProt Accession
GCYA2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:8784
GenAtlas
PDE5A
GeneCards
PDE5A
GenBank Gene Database
AF043731
GenBank Protein Database
3420185
Guide to Pharmacology
1304
UniProt Accession
PDE5A_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72